{"product_id":"drug-and-therapy-development-for-triple-negative-breast-cancer-9783527351756","title":"Drug and Therapy Development for Triple Negative","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eDrug and Therapy Development for  Triple Negative Breast Cancer\u003c\/b\u003e \u003cp\u003e\u003cb\u003eThe first comprehensive and up-to-date compilation of modern diagnostic and treatment methods for triple negative breast cancer\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eIn \u003ci\u003eDrug and Therapy Development for Triple Negative Breast Cancer\u003c\/i\u003e, a team of distinguished practitioners delivers an in-depth and authoritative discussion  of contemporary methods for treating triple negative breast cancer (TNBC). The editors have included material that covers its molecular causes, initial detection, diagnostic tools, treatment procedures, pharmacology, and new and experimental therapies—including nanotherapeutics and photothermal therapies. \u003c\/p\u003e\u003cp\u003eAs the first comprehensive compilation of modern treatment methods for TNBC, this reference is an unmatched source of information about current and future treatment approaches, including machine learning methods for earlier detection and more accurate diagnosis. Readers will also find: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eA thorough introduction to HER receptors in breast cancers\u003c\/li\u003e\n\u003cli\u003eComprehensive explorations of the etiology and therapy of hormone receptor-positive breast cancer and the early-stage diagnosis of breast cancer\u003c\/li\u003e\n\u003cli\u003eApplication of artificial intelligence to breast cancer diagnosis\u003c\/li\u003e\n\u003cli\u003eNew insights on the role of DNA replication stress and genome instability in breast cancer\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003ePerfect for medicinal and pharmaceutical chemists, \u003ci\u003eDrug and Therapy Development for Triple Negative Breast Cancer\u003c\/i\u003e will also benefit oncologists and professionals working in the pharmaceutical industry or in hospital settings.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I History of Breast Cancer 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Early-Stage Diagnosis of Breast Cancer: Amelioration in Approaches 3\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNidhi Manhas, Lalita S. Kumar, and Vinayak Adimule\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 3\u003c\/p\u003e \u003cp\u003e1.2 Imaging Techniques 4\u003c\/p\u003e \u003cp\u003e1.2.1 Mammography (MG) 4\u003c\/p\u003e \u003cp\u003e1.2.2 Ultrasonography (US) 7\u003c\/p\u003e \u003cp\u003e1.2.3 Magnetic Resonance Imaging (MRI) 8\u003c\/p\u003e \u003cp\u003e1.3 Microwave Breast Imaging Methods 10\u003c\/p\u003e \u003cp\u003e1.3.1 Microwave Tomography 11\u003c\/p\u003e \u003cp\u003e1.3.2 Radio-Based Microwave Imaging 12\u003c\/p\u003e \u003cp\u003e1.4 Biomarkers and Biosensors for Breast Cancer Detection 14\u003c\/p\u003e \u003cp\u003e1.4.1 Biomarkers 15\u003c\/p\u003e \u003cp\u003e1.4.1.1 Nucleic Acids 15\u003c\/p\u003e \u003cp\u003e1.4.1.2 Proteins 15\u003c\/p\u003e \u003cp\u003e1.4.1.3 Tumor Cells 16\u003c\/p\u003e \u003cp\u003e1.4.2 Biosensors 16\u003c\/p\u003e \u003cp\u003e1.4.2.1 Electrochemical Biosensors 16\u003c\/p\u003e \u003cp\u003e1.4.2.2 Optical Sensors 17\u003c\/p\u003e \u003cp\u003e1.5 Conclusion 19\u003c\/p\u003e \u003cp\u003eAcknowledgment 20\u003c\/p\u003e \u003cp\u003eReferences 20\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 DNA Replication Stress and Genome Instability in Breast Cancer 35\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eKirti Sinha, Pau B. Sang, Priyanka Sharma, and Rishi K. Jaiswal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 35\u003c\/p\u003e \u003cp\u003e2.2 Causes of Replication Stress and Genomic Instability 36\u003c\/p\u003e \u003cp\u003e2.2.1 Replication Dysfunction 36\u003c\/p\u003e \u003cp\u003e2.2.1.1 Low and Untimely Initiation of Replication 36\u003c\/p\u003e \u003cp\u003e2.2.1.2 Replication Fork Maintenance 37\u003c\/p\u003e \u003cp\u003e2.2.1.3 Mitotic Defects 38\u003c\/p\u003e \u003cp\u003e2.2.2 Transcription-Induced Stress 40\u003c\/p\u003e \u003cp\u003e2.2.2.1 Failed Post-Replication Repair 40\u003c\/p\u003e \u003cp\u003e2.2.3 Genomic Aberrations and Instability 40\u003c\/p\u003e \u003cp\u003e2.2.3.1 Site-Specific Hotspots 40\u003c\/p\u003e \u003cp\u003e2.2.3.2 Amplifier Genome 41\u003c\/p\u003e \u003cp\u003e2.2.3.3 Replication in Inappropriate Metabolic Conditions 41\u003c\/p\u003e \u003cp\u003e2.3 Molecular Mechanism of Genomic Instability 42\u003c\/p\u003e \u003cp\u003e2.3.1 Problems Faced During DNA Damage Repair 43\u003c\/p\u003e \u003cp\u003e2.3.2 Transcriptional Stress 44\u003c\/p\u003e \u003cp\u003e2.3.3 CIN: Result of Defective Mitosis 45\u003c\/p\u003e \u003cp\u003e2.4 Aftermath of Replication Stress on Cell and Its Fate 46\u003c\/p\u003e \u003cp\u003e2.4.1 Conservation of Stalled Replication Forks 46\u003c\/p\u003e \u003cp\u003e2.4.2 Chromosome Segregation Defect Check by HR Repair 47\u003c\/p\u003e \u003cp\u003e2.4.3 Aging, Cell Death, and Senescence 47\u003c\/p\u003e \u003cp\u003e2.5 Therapeutic Approach 48\u003c\/p\u003e \u003cp\u003e2.6 Conclusion 50\u003c\/p\u003e \u003cp\u003eReferences 51\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Recent Advancement of Nanotherapeutics to Treat Breast Cancer 65\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDevesh U. Kapoor, Rajat Goyal, Rajiv R. Kukkar, and Rupesh K. Gautam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 65\u003c\/p\u003e \u003cp\u003e3.2 Pathophysiology of Breast Cancer 66\u003c\/p\u003e \u003cp\u003e3.3 Classification of Breast Cancer 66\u003c\/p\u003e \u003cp\u003e3.4 Techniques for Breast Cancer Detection 68\u003c\/p\u003e \u003cp\u003e3.5 Current Breast Cancer Therapies 68\u003c\/p\u003e \u003cp\u003e3.6 Nanotherapeutics for Breast Cancer Treatment and Metastasis 69\u003c\/p\u003e \u003cp\u003e3.6.1 Nanodiamonds (NDs) 69\u003c\/p\u003e \u003cp\u003e3.6.2 Intrinsic Toxicity Reduction 69\u003c\/p\u003e \u003cp\u003e3.6.3 Diminishing Chemoresistance (CR) 70\u003c\/p\u003e \u003cp\u003e3.6.4 Delivery of Combination Therapeutics Through NDs 70\u003c\/p\u003e \u003cp\u003e3.7 Polymer-Based Nanoparticles (PBNPs) 71\u003c\/p\u003e \u003cp\u003e3.8 Inorganic Nanoparticles (IONPs) 72\u003c\/p\u003e \u003cp\u003e3.9 Hydrogels (HGLs) and Microbubbles (MBs) 74\u003c\/p\u003e \u003cp\u003e3.10 Recent Patents of Nanotherapeutics for Breast Cancer Treatment 76\u003c\/p\u003e \u003cp\u003e3.11 Clinical Trials of Nanotherapeutics for Breast Cancer 76\u003c\/p\u003e \u003cp\u003e3.12 Conclusion and Future Perspectives 77\u003c\/p\u003e \u003cp\u003eReferences 78\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 HER Receptor in Breast Cancer 85\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGuno S. Chakraborthy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 85\u003c\/p\u003e \u003cp\u003e4.2 Role of HER Receptors in the Human Body 86\u003c\/p\u003e \u003cp\u003e4.3 HER2 Receptor in Breast Cancer Progression 88\u003c\/p\u003e \u003cp\u003e4.4 Conclusion 88\u003c\/p\u003e \u003cp\u003eReferences 89\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Human Endogenous Retroviruses in Triple-Negative Breast Cancer 93\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTara P. Hurst, Timokratis Karamitros, and Gkikas Magiorkinis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 93\u003c\/p\u003e \u003cp\u003e5.2 HERVs in Breast Cancer and TNBC 95\u003c\/p\u003e \u003cp\u003e5.3 TROJAN lncRNA and TNBC 96\u003c\/p\u003e \u003cp\u003e5.4 HERVs and Breast Cancer Treatments 97\u003c\/p\u003e \u003cp\u003e5.5 Conclusion 97\u003c\/p\u003e \u003cp\u003e5.6 Search Strategy 97\u003c\/p\u003e \u003cp\u003eReferences 98\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Novel Drug Discovery and Development 103\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Development in Drug Repurposing for the Treatment of Acute Leukemia Complicating Metastatic Breast Cancer 105\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNilophar M. Shaikh, Vinayak Adimule, and Santosh Nandi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 105\u003c\/p\u003e \u003cp\u003e6.1.1 Acute Leukemia’s 107\u003c\/p\u003e \u003cp\u003e6.1.2 Mitochondrial cAMP–PKA Signaling 110\u003c\/p\u003e \u003cp\u003e6.1.3 Nuclear Compartment 110\u003c\/p\u003e \u003cp\u003e6.1.4 Cytosolic Compartment and Plasma Membrane 110\u003c\/p\u003e \u003cp\u003e6.2 Conclusion 111\u003c\/p\u003e \u003cp\u003eReferences 111\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Novel Pharmaceutical Nanomaterials to Advance the Current Breast Cancer Treatment – Current Trends and Future Perspective 117\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSteven Mufamadi, Mpho Ngoepe, Aidan Battison, and Itumeleng Zosela\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 117\u003c\/p\u003e \u003cp\u003e7.2 Graphene-Based Nanomaterials for Breast Cancer 119\u003c\/p\u003e \u003cp\u003e7.3 Light-Based Nanotechnology for Breast Cancer 120\u003c\/p\u003e \u003cp\u003e7.3.1 Photodynamic Therapeutic Nanomaterials 120\u003c\/p\u003e \u003cp\u003e7.3.2 Photothermal Therapeutic Nanomaterials 122\u003c\/p\u003e \u003cp\u003e7.4 Green Synthesis of Gold Nanoparticles for Breast Cancer 122\u003c\/p\u003e \u003cp\u003e7.5 Nanocarriers for Gene Therapy and Immunotherapy 124\u003c\/p\u003e \u003cp\u003e7.6 Conclusion and Recommendations 125\u003c\/p\u003e \u003cp\u003eReferences 125\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Advanced Technologies in Breast Cancer Therapy 131\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Artificial Intelligence-Driven Decisions in Breast Cancer Diagnosis 133\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAmit Gangwal and Rupesh K. Gautam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 133\u003c\/p\u003e \u003cp\u003e8.2 Breast Cancer 135\u003c\/p\u003e \u003cp\u003e8.3 Diagnosis of Breast Cancer 136\u003c\/p\u003e \u003cp\u003e8.4 Artificial Intelligence 138\u003c\/p\u003e \u003cp\u003e8.4.1 Artificial Intelligence and Medical Imaging 140\u003c\/p\u003e \u003cp\u003e8.5 Conclusion 142\u003c\/p\u003e \u003cp\u003e8.6 Future Challenges 142\u003c\/p\u003e \u003cp\u003eReferences 144\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Establishing Nanotechnology-Based Drug Development for Triple- Negative Breast Cancer Treatment 153\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRavinder Verma, Shailendra Bhatt, Rohit Dutt, Manish Kumar, Deepak Kaushik, and Rupesh K. Gautam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 153\u003c\/p\u003e \u003cp\u003e9.2 Triple-Negative Breast Cancer 154\u003c\/p\u003e \u003cp\u003e9.2.1 Molecular Mechanisms (Signaling Pathways) Involved in TNBC Therapeutics 156\u003c\/p\u003e \u003cp\u003e9.2.1.1 Notch Signaling Pathway 156\u003c\/p\u003e \u003cp\u003e9.2.1.2 Hedgehog Signaling Pathway 156\u003c\/p\u003e \u003cp\u003e9.2.1.3 Wnt\/β-Catenin 156\u003c\/p\u003e \u003cp\u003e9.2.1.4 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors 157\u003c\/p\u003e \u003cp\u003e9.2.1.5 EGFR 157\u003c\/p\u003e \u003cp\u003e9.2.1.6 Mammalian Target of Rapamycin (mTOR) Inhibitors 157\u003c\/p\u003e \u003cp\u003e9.2.1.7 TGF-β Signaling Pathway 158\u003c\/p\u003e \u003cp\u003e9.2.1.8 CSPG4 (Chondroitin Sulfate Proteoglycan) Protein Signaling Pathway 158\u003c\/p\u003e \u003cp\u003e9.2.2 Conventional Therapeutics 158\u003c\/p\u003e \u003cp\u003e9.2.3 Promising Nanotechnology Innovations for TNBC Therapy 159\u003c\/p\u003e \u003cp\u003e9.2.3.1 Nanoparticles (NPs) 160\u003c\/p\u003e \u003cp\u003e9.2.3.2 Nanoconjugates 162\u003c\/p\u003e \u003cp\u003e9.2.3.3 Quantum Dots (QDs) 162\u003c\/p\u003e \u003cp\u003e9.2.3.4 Nano-Diamonds (NDs) 162\u003c\/p\u003e \u003cp\u003e9.2.3.5 Nanocomposites 163\u003c\/p\u003e \u003cp\u003e9.2.3.6 Nano-Matryoshkas 163\u003c\/p\u003e \u003cp\u003e9.2.3.7 Polymeric Micelles (PM): A Miracle Ball in Cancer Therapy 163\u003c\/p\u003e \u003cp\u003e9.2.3.8 Dendrimers 163\u003c\/p\u003e \u003cp\u003e9.2.3.9 Folded Graphene: Carbon nanotubes (CNTs) 164\u003c\/p\u003e \u003cp\u003e9.2.3.10 Virus-Like Particles (VLPs) as Novel Nanovesicles 164\u003c\/p\u003e \u003cp\u003e9.2.3.11 Liposomes 164\u003c\/p\u003e \u003cp\u003e9.2.4 Vaccines Under the Clinical Trial (CT) for TNBC Treatment 165\u003c\/p\u003e \u003cp\u003e9.2.4.1 Peptide-Based Vaccines 166\u003c\/p\u003e \u003cp\u003e9.2.4.2 Viral Vector-Based Vaccines 166\u003c\/p\u003e \u003cp\u003e9.2.4.3 Gene-Based Vaccines 166\u003c\/p\u003e \u003cp\u003e9.2.5 USFDA-Approved Clinical Trials 166\u003c\/p\u003e \u003cp\u003e9.2.6 Current Status of TNBC Treatment 167\u003c\/p\u003e \u003cp\u003e9.2.7 Recent Patents Based on Nanoformulations for TNBC Treatment 167\u003c\/p\u003e \u003cp\u003e9.3 Challenges 168\u003c\/p\u003e \u003cp\u003e9.4 Future Perspectives on TNBC Metastasis Therapy 168\u003c\/p\u003e \u003cp\u003e9.4.1 NEO Adjuvant Modeling 169\u003c\/p\u003e \u003cp\u003e9.4.2 Execution of In Vivo Genetic Screening 169\u003c\/p\u003e \u003cp\u003e9.4.3 Identification of Effective Drugs for TNBC 169\u003c\/p\u003e \u003cp\u003e9.4.4 Synergistic Effect of Drugs that Almost Eliminate Tumor 169\u003c\/p\u003e \u003cp\u003e9.5 Conclusion 169\u003c\/p\u003e \u003cp\u003eReferences 170\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Etiology and Therapy of Hormone Receptor-Positive Breast Cancer 181\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNalini Kurup and Darshana Warekar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 181\u003c\/p\u003e \u003cp\u003e10.2 Etiology 182\u003c\/p\u003e \u003cp\u003e10.2.1 Role of Estrogen Hormone 182\u003c\/p\u003e \u003cp\u003e10.2.2 Role of Progesterone Hormone 182\u003c\/p\u003e \u003cp\u003e10.2.3 Estrogen Receptor (ER) 183\u003c\/p\u003e \u003cp\u003e10.2.4 Progesterone Receptor (PR) 184\u003c\/p\u003e \u003cp\u003e10.3 Human Epidermal Growth Factor-2 (HER-2) 184\u003c\/p\u003e \u003cp\u003e10.4 Various Types of Breast Cancer Detected Under Hormone Receptor Breast Cancer 185\u003c\/p\u003e \u003cp\u003e10.4.1 Estrogen Receptor (ER) Positive 185\u003c\/p\u003e \u003cp\u003e10.4.2 Progesterone Receptor (PR) Positive 185\u003c\/p\u003e \u003cp\u003e10.4.3 Hormone Receptor (HR) Negative 185\u003c\/p\u003e \u003cp\u003e10.5 Detection 186\u003c\/p\u003e \u003cp\u003e10.6 Therapy 187\u003c\/p\u003e \u003cp\u003e10.6.1 Selective Estrogen-Receptor Response Modulators (SERMs) 188\u003c\/p\u003e \u003cp\u003e10.6.2 Aromatase Inhibitors 188\u003c\/p\u003e \u003cp\u003e10.6.3 Estrogen-Receptor Down Regulators (ERDs) 188\u003c\/p\u003e \u003cp\u003e10.6.4 Luteinizing Hormone-Releasing Hormone Agents (LHRH) 189\u003c\/p\u003e \u003cp\u003e10.7 Limitations of Hormone Therapy 190\u003c\/p\u003e \u003cp\u003e10.7.1 Tamoxifen 190\u003c\/p\u003e \u003cp\u003e10.7.2 Raloxifene 190\u003c\/p\u003e \u003cp\u003e10.7.3 Aromatase Inhibitors 190\u003c\/p\u003e \u003cp\u003e10.7.4 Fulvestrant 191\u003c\/p\u003e \u003cp\u003e10.8 Triple-Negative Breast Cancer 191\u003c\/p\u003e \u003cp\u003e10.8.1 Clinical History of Triple-Negative Breast Cancer 191\u003c\/p\u003e \u003cp\u003e10.8.2 Imaging Characteristics\/Features of Triple-Negative Breast Cancer 191\u003c\/p\u003e \u003cp\u003e10.8.3 Subtypes of TNBC 192\u003c\/p\u003e \u003cp\u003e10.8.3.1 Basal-Like Subtype: (i) BL1 (ii) BL 2 192\u003c\/p\u003e \u003cp\u003e10.8.3.2 Claudine Low Subtype 192\u003c\/p\u003e \u003cp\u003e10.8.3.3 Immunomodulatory Subtype (IM) 192\u003c\/p\u003e \u003cp\u003e10.8.3.4 Mesenchymal Subtype (M) 192\u003c\/p\u003e \u003cp\u003e10.8.3.5 Mesenchymal Stem-Like Subtype (MSL) 192\u003c\/p\u003e \u003cp\u003e10.8.3.6 Luminal Androgen Receptor Subtype (LAR) 193\u003c\/p\u003e \u003cp\u003e10.8.4 Treatment of Triple-Negative Breast Cancer 193\u003c\/p\u003e \u003cp\u003e10.8.5 Advance TNBC 193\u003c\/p\u003e \u003cp\u003e10.8.6 Pharmacogenomics 194\u003c\/p\u003e \u003cp\u003e10.9 Conclusion 195\u003c\/p\u003e \u003cp\u003eReferences 196\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Donor–Acceptor-Based Heterocyclic Compounds as Chemotherapy and Photothermal Agents in Treatment of Breast Cancer Cell 201\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eVinayak M. Adimule, Sheetal R. Batakurki, Maya M. Pai, and Santosh Nandi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 201\u003c\/p\u003e \u003cp\u003e11.2 Causes for Breast Cancer 202\u003c\/p\u003e \u003cp\u003e11.3 Imaging and Screening of Breast Cancer 202\u003c\/p\u003e \u003cp\u003e11.4 Photothermal Therapy (PTT) 203\u003c\/p\u003e \u003cp\u003e11.5 Acceptor–Donor-Based Heterocyclic Compounds 208\u003c\/p\u003e \u003cp\u003e11.6 Examples of Organic-Based Donor–Acceptor 210\u003c\/p\u003e \u003cp\u003e11.6.1 Indocyanine 210\u003c\/p\u003e \u003cp\u003e11.7 Polymers-Based Agents 211\u003c\/p\u003e \u003cp\u003e11.7.1 Phthalocyanine 211\u003c\/p\u003e \u003cp\u003e11.8 Conclusion 212\u003c\/p\u003e \u003cp\u003eReferences 213\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Regulatory, Clinical Aspects and Case Studies 221\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 An Insight into Drug Regulatory Affairs and the Procedures 223\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eShaik A. Begum and Joshna Rani S\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Endpoints of Clinical Trials for the Approval of Cancer Drugs and Biologics 223\u003c\/p\u003e \u003cp\u003e12.2 Statutory and Regulatory Requirements for Effectiveness 223\u003c\/p\u003e \u003cp\u003e12.2.1 Endpoints Supporting Previous Oncology Approvals 224\u003c\/p\u003e \u003cp\u003e12.2.2 Endpoints Based on Tumor Assessments 225\u003c\/p\u003e \u003cp\u003e12.2.3 Clinical Practice Guideline for the Diagnosis, Staging, and Treatment of Patients with Metastatic Breast Cancer 225\u003c\/p\u003e \u003cp\u003e12.2.4 Cancer Drug and Diagnostic Regulation by the FDA 226\u003c\/p\u003e \u003cp\u003e12.2.5 Considerations for Clinical Trial Design and Analysis 227\u003c\/p\u003e \u003cp\u003e12.2.6 Single-Arm Studies 227\u003c\/p\u003e \u003cp\u003e12.2.7 Randomized Studies Designed to Demonstrate Noninferiority 227\u003c\/p\u003e \u003cp\u003e12.3 Clinical Trial Design Considerations 228\u003c\/p\u003e \u003cp\u003e12.4 Clinical Trial Analysis Issues 228\u003c\/p\u003e \u003cp\u003e12.5 Use of Pathological Complete Response as an Endpoint to Support Accelerated Approval in Neoadjuvant Treatment of High-Risk Early- Stage Breast Cancer 228\u003c\/p\u003e \u003cp\u003e12.6 Developing Treatments for Premenopausal Women with Breast Cancer 229\u003c\/p\u003e \u003cp\u003e12.7 Recommendations by FDA 230\u003c\/p\u003e \u003cp\u003e12.7.1 Access to Experimental Cancer Drugs 230\u003c\/p\u003e \u003cp\u003e12.7.2 How to Get a Hold of an Experimental Drug 230\u003c\/p\u003e \u003cp\u003e12.7.3 Access to More Information (Compassionate Use) 231\u003c\/p\u003e \u003cp\u003e12.8 What is Right to Try? 231\u003c\/p\u003e \u003cp\u003e12.9 Examples of Drugs Approved for Breast Cancer 232\u003c\/p\u003e \u003cp\u003eReferences 233\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 A Comprehensive Review of Some Heat-Shock Proteins in the Development and Progression of Human Breast Cancer 237\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eXolani H. Makhoba and Ofentse J. Pooe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 237\u003c\/p\u003e \u003cp\u003e13.1.1 Cancer and Its Economic Burden on Human 238\u003c\/p\u003e \u003cp\u003e13.2 Structure-Functional Features of HSPs 239\u003c\/p\u003e \u003cp\u003e13.2.1 Heat-Shock Protein 40 239\u003c\/p\u003e \u003cp\u003e13.2.2 Heat-Shock Protein 60 239\u003c\/p\u003e \u003cp\u003e13.2.3 Heat-Shock Protein 70 240\u003c\/p\u003e \u003cp\u003e13.2.4 Heat-Shock Protein 90 241\u003c\/p\u003e \u003cp\u003e13.3 Conclusion and Future Perspectives 242\u003c\/p\u003e \u003cp\u003eAcknowledgments 244\u003c\/p\u003e \u003cp\u003eReferences 244\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Nanoparticle-Based Therapeutics for Triple Negative Breast Cancer 249\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eIsidore A. Egebe and Kamalinder K. Singh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Breast Cancer: State of Research and Practice 249\u003c\/p\u003e \u003cp\u003e14.2 Triple Negative Breast Cancer (TNBC) and Treatment Approaches 252\u003c\/p\u003e \u003cp\u003e14.3 Nanoparticle Therapeutics for TNBC 253\u003c\/p\u003e \u003cp\u003e14.3.1 Metallic Nanoparticles 255\u003c\/p\u003e \u003cp\u003e14.3.1.1 Gold Nanoparticles (AuNPs) 255\u003c\/p\u003e \u003cp\u003e14.3.1.2 Silver Nanoparticles (AgNPs) 255\u003c\/p\u003e \u003cp\u003e14.3.2 Dendrimers 255\u003c\/p\u003e \u003cp\u003e14.3.3 Lipid-Based Nanoparticles (LNPs) 256\u003c\/p\u003e \u003cp\u003e14.3.3.1 Liposomes 256\u003c\/p\u003e \u003cp\u003e14.3.3.2 Nanoemulsions (NEs) 258\u003c\/p\u003e \u003cp\u003e14.3.3.3 Solid Lipid Nanoparticles (SLNs) 259\u003c\/p\u003e \u003cp\u003e14.3.3.4 Nanostructured Lipid Carriers (NLCs) 259\u003c\/p\u003e \u003cp\u003e14.3.3.5 Lipid Polymer Hybrid Nanoparticles (LPH-NPs) 260\u003c\/p\u003e \u003cp\u003e14.3.4 CRISPR Nanoparticles 261\u003c\/p\u003e \u003cp\u003e14.3.5 Exosomes (Exo) 261\u003c\/p\u003e \u003cp\u003e14.3.6 Nucleic Acid (NAs)-Based Therapeutics 262\u003c\/p\u003e \u003cp\u003e14.4 Ligands Used to Enhance Nanoparticle Therapeutics in TNBC 262\u003c\/p\u003e \u003cp\u003e14.4.1 Antibodies 262\u003c\/p\u003e \u003cp\u003e14.4.2 Peptides 262\u003c\/p\u003e \u003cp\u003e14.4.3 Aptamers 263\u003c\/p\u003e \u003cp\u003e14.4.4 Small Molecules 263\u003c\/p\u003e \u003cp\u003e14.5 Conclusion 263\u003c\/p\u003e \u003cp\u003eReferences 264\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Current Updates in Breast Cancer Drugs 273\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNitu L. Wankhede, Mayur B. Kale, Pranali A. Chandurkar, Manish M. Aglawe, Ashwini K. Bawankule, Brijesh G. Taksande, Milind J. Umekar, Rupesh K. Gautam, and Aman B. Upaganlawar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 273\u003c\/p\u003e \u003cp\u003e15.2 Therapeutic Approaches 274\u003c\/p\u003e \u003cp\u003e15.2.1 Hormonotherapy 275\u003c\/p\u003e \u003cp\u003e15.2.2 Chemotherapy 276\u003c\/p\u003e \u003cp\u003e15.3 Targeted Therapy 276\u003c\/p\u003e \u003cp\u003e15.3.1 Drug Repurposing 276\u003c\/p\u003e \u003cp\u003e15.3.2 HER2 Inhibitors 278\u003c\/p\u003e \u003cp\u003e15.3.3 PARP Inhibitors 280\u003c\/p\u003e \u003cp\u003e15.3.4 Immunotherapy 280\u003c\/p\u003e \u003cp\u003e15.3.5 Others Novel Targets 281\u003c\/p\u003e \u003cp\u003e15.3.5.1 Histone Deacetylase (HDAC) Inhibitors 281\u003c\/p\u003e \u003cp\u003e15.3.5.2 Angiogenesis Inhibitors 281\u003c\/p\u003e \u003cp\u003e15.4 Conclusion 284\u003c\/p\u003e \u003cp\u003eAcknowledgment 284\u003c\/p\u003e \u003cp\u003eReferences 285\u003c\/p\u003e \u003cp\u003eIndex 295\u003c\/p\u003e","brand":"Wiley-VCH Verlag GmbH","offers":[{"title":"Default Title","offer_id":49419455594839,"sku":"9783527351756","price":999.99,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/drug-and-therapy-development-for-triple-negative-breast-cancer-9783527351756","provider":"Book Curl","version":"1.0","type":"link"}